ARK Innovation ETF vs Citius Pharmaceuticals Inc — how do they compare? ARK Innovation ETF trades at $81.34, while Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M). The key difference: ARK Innovation ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ARKK | CTXR | |
|---|---|---|
52-Week High | $92.50 | $1.82 |
52-Week Low | $63.52 | $0.48 |
Market Cap | — | $20.01M |
Sector | — | Health |
Enterprise Value | — | $16.23M |
Trailing returns across standard periods
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →